Home
This site is intended for healthcare professionals

From Ideal to Real: Making Guideline-Based Treatment Decisions for Bladder Cancer in Every Care Setting

17th Jun 2026
11:00pm - 12:15am (GMT)
17th - 18th Jun 2026
11:00pm - 12:15am (GMT)
Hosted on MedAll
Attendance certificate available
This event has ended. Similar events
Free
Online

Description

This program is supported by an independent education grant from MSD. This online education program has been designed solely for healthcare professionals in the US. The content is not intended for healthcare professionals in any other country.

Join leading bladder cancer experts Dr. Petros Grivas and Dr. Benjamin Garmezy for this accredited live online teaching session. Using three progressive, case-based role-play scenarios, this session explores the "ideal vs. real" complexities of managing bladder cancer across diverse practice environments.

By adopting specific hospital, community, and rural perspectives, the faculty will illustrate how to translate diagnostic findings into guideline-aligned treatment decisions despite real-world system constraints. Participants will gain practical insights into navigating resource limitations, strengthening multidisciplinary care coordination, and implementing escalation pathways for NMIBC, MIBC, and metastatic disease to ensure consistent, high-quality care in every setting.

Credits: AMA PRA Category 1 Credits™ (1.25.00 hours)

Session Highlights

  • Navigating High-Risk NMIBC Escalation: Contrast guideline-ideal TURBT and BCG timing with the practical realities of rural care, focusing on safe treatment adaptations when pathology or resection access is limited.
  • Preserving Curative Intent in MIBC: Identify strategies to maintain the cisplatin-to-cystectomy sequence despite systemic barriers, including imaging delays, surgical access gaps, and patient travel constraints.
  • Systemic Therapy & Referral Triggers: Define clear "treat here vs. refer now" criteria for advanced urothelial carcinoma to manage monitoring logistics and follow-up care across diverse clinical settings.

Who Should Watch

This program is designed for healthcare professionals in the US, directly involved in diagnosing, staging, and managing bladder cancer and making treatment-planning decisions across community, rural, and hospital settings, including:

  • Urologists (generalists, community urologists, and academic specialists)
  • Medical Oncologists involved in bladder cancer management
  • Advanced Practice Providers (nurse practitioners, physician associates) in urology and oncology
  • Urology Nurses and Oncology Nurses
  • Primary Care Clinicians in community or rural settings who participate in referral decisions
  • Allied Health Professionals supporting bladder cancer coordination and follow-up

Presented by

Petros Grivas, MD, PhD is an oncologist with expertise in treating genitourinary cancers such as bladder cancer, prostate cancer and testicular cancer. His clinical research helped lead to FDA approval of new drugs to treat the most common type of bladder cancer. Dr. Grivas currently leads clinical trials that investigate the use of checkpoint inhibitors. These immunotherapy drugs release the brakes on a patient’s immune system and help it mount a better response to cancer.

Benjamin Garmezy, MD is a board-certified medical oncologist and the Associate Director of Genitourinary Research at Sarah Cannon Research Institute (SCRI). With a deep clinical interest in prostate, kidney, bladder, and testicular cancers, he oversees the development of novel investigational therapies. A frequent faculty member at major international congresses including ASCO and ESMO, Dr. Garmezy has published extensively on clinical trial design and has authored over 50 abstracts focused on advancing the standard of care in GU oncology.

Continuing Education Information

This activity received monetary support through an independent education grant from MSD.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Petros Grivas, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consulting for MSD, BMS, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology AbbVie, Bicycle Therapeutics, Replimune, Daiichi Sankyo, Foundation Medicine, Eli Lilly, Urogen, Tyra, Natera; Research funding paid to institution EMD Serono, Acrivon Therapeutics, ALX Oncology, MSD, Gilead Sciences, Genentech. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Grivas may reference any unlabeled or unapproved uses of products during the presentation. He will disclose to the audience when this discussion takes place.

Benjamin Garmezy, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consulting for Adaptimmune, Adicent Therapeutics, AIQ Global, Amgen, AstraZeneca, Bayer, Bicycle Tx, BioNTech, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, Genentech/Roche, GlaxoSmithKline, Janssen, Merck, Monte Rosa Therapeutics, Novartis, Onviv, Pfizer, Rondo Therapeutics, Seagen, Specialty Networks, Takeda Pharmaceuticals, Xencor; Research funding paid to institution Abbvie, Accutar Biotechnology, Adcentrx Therapeutics, Adicet Therapeutics, Amgen, Arcus Biosciences, Arvinas, AstraZeneca, Avenzo Therapeutics, AVEO Oncology, Bicycle Therapeutics, Bristol-Myers Squibb, CRISPR Therapeutics, Daiichi Sankyo, Eikon Therapeutics, Exelixis, Roche/Genentech, Flare Therapeutics, GlaxoSmithKline, Halda Therapeutics, Harbour BioMed, HiberCell, IDEAYA Biosciences, Incyte, Janssen, Janux Therapeutics, Jubilant Therapeutics, Kineta, Kinnate BioPharma, Loxo, Merck, Mink Therapeutics, Novartis, Nuvation Bio, Pfizer, Profound Bio, Rise Therapeutics, Rondo Therapeutics, Takeda Therapeutics, Teon Therapeutics, TMUNITY Therapeutics, Xencor, Zenshine. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Garmezy does not intend to discuss non-FDA uses of drug products and/or devices.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Pharmacists

Pharmacists AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).

CE Title: Aligned Care in Bladder Cancer: A Curriculum for Guideline-Based Management Across Community, Rural, and Hospital Settings - Virtual Live

Activity Type: Knowledge based

UAN: 0829-9999-26-103-L01-P

Contact Hours: 1.25

No cost to participate.

Participant CE records will be electronically communicated to CPE Monitor.

Pharmacist Learning Objectives

At the conclusion of this web conference, participants should be able to:

1. Interpret key diagnostic and prognostic markers, including pathology, imaging, and clinical risk factors, to support risk assessment in diverse care settings.

2. Apply diagnostic findings to determine when to escalate care, refer, or adjust treatment planning based on available local resources.

3. Design and implement guideline-aligned treatment pathways for high-risk NMIBC, MIBC, and metastatic disease, accounting for workflow and access challenges in community and rural practices.

4. Implement practical strategies to navigate resource limitations and strengthen care coordination to support consistent bladder cancer management.

Criteria for Claiming CPE Credit: Participants must have registered and attended the entire program. Attendance is monitored online for participation in the entire activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

  • When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
  • Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting June 17th 2026 and will expire on June 17th 2026. Estimated time to complete this activity: 75 minutes.

Learning objectives

Upon completion of this learning activity, participants will be able to:

  • Interpret key diagnostic and prognostic markers, including pathology, imaging, and clinical risk factors, to support risk assessment in diverse care settings.
  • Apply diagnostic findings to determine when to escalate care, refer, or adjust treatment planning based on available local resources.
  • Design and implement guideline-aligned treatment pathways for high-risk NMIBC, MIBC, and metastatic disease, accounting for workflow and access challenges in community and rural practices.
  • Implement practical strategies to navigate resource limitations and strengthen care coordination to support consistent bladder cancer management.
View all

Similar events and on demand videos

 
17th - 18th Jun 2026
11:00pm - 12:15am (GMT)
Hosted on MedAll
Attendance certificate available
This event has ended. Similar events
Free
Online